Breaking Down Lihuayi Weiyuan Chemical Co., Ltd. Financial Health: Key Insights for Investors

Investors reviewing Lihuayi Weiyuan Chemical Co., Ltd. will find a mix of growth and strain: Q1 2025 revenue rose to CNY 2.41 billion (up 12.4% YoY) while TTM revenue as of Sep 30, 2025 stood at CNY 9.06 billion (down 2.95% YoY) after a noteworthy full-year 2024 revenue of CNY 9.52 billion (a 35.06% jump from CNY 7.05 billion in 2023), with revenue per employee in 2024 near CNY 5.85 million and a market capitalization of CNY 7.75 billion (up 9.77% YoY) at Oct 28, 2025 and a P/S of 0.86; profitability flags are stark - Q1 2025 reported a net loss of CNY 162.61 million versus net income of CNY 19.09 million in Q1 2024, TTM EPS is CNY -0.38 with negative net profit margin and ROE, operating cash flow TTM is CNY 917.9 million but free cash flow is CNY -551 million, while the balance sheet shows total debt of CNY 2.89 billion against cash of CNY 844 million, an enterprise value of CNY 9.50 billion, beta 0.71 and EV/EBIT at -99.55; dividend per share is CNY 0.03 (yield 0.21%), and the company's capacity investments, Dongying location and product mix present growth levers worth a closer look - dive into the full analysis for detailed liquidity, solvency, valuation and risk breakdowns.

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Revenue Analysis

Key revenue dynamics for Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) show divergent short‑ and long‑term trends: strong year‑over‑year growth in 2024, a modest contraction on a trailing twelve‑month basis to September 30, 2025, and a solid start to 2025 in Q1.

• Q1 2025 revenue: CNY 2.41 billion, up 12.4% from CNY 2.14 billion in Q1 2024.
• TTM revenue as of 2025‑09‑30: CNY 9.06 billion, down 2.95% vs. prior-year CNY 9.52 billion.
• Full‑year 2024 revenue: CNY 9.52 billion, up 35.06% from CNY 7.05 billion in 2023.
• Revenue per employee (2024): ≈ CNY 5.85 million based on 1,548 employees.
• Market capitalization (2025‑10‑28): CNY 7.75 billion, +9.77% year‑over‑year.
• Price‑to‑Sales (P/S) ratio (2025‑10‑28): 0.86.

Revenue composition and trajectory notes:

• 2024 was a high‑growth year driven by product mix, capacity utilization and favorable market conditions, yielding a +35.06% jump in annual revenue.
• TTM through 2025‑09‑30 shows a modest contraction (-2.95%) indicating either seasonal softness, product price pressure, or reduced volumes after the 2024 peak.
• Q1 2025 rebound (+12.4% YoY) suggests improving top‑line momentum early in 2025, though TTM still lags the prior 12 months.
• With a market cap of CNY 7.75 billion and P/S of 0.86, investors are pricing Lihuayi Weiyuan at less than 1x sales, reflecting valuation caution despite robust 2024 growth.

For corporate background and how the company generates revenue, see Lihuayi Weiyuan Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Profitability Metrics

• Q1 2025 net result: net loss of CNY 162.61 million (vs. net income of CNY 19.09 million in Q1 2024).
• Twelve-months ending Sep 30, 2025: negative net profit margin and EPS of CNY -0.38.
• Return on equity (ROE): negative, indicating shareholders' capital has not produced positive returns in the period.
• Operating cash flow (TTM): CNY 917.9 million - solid cash from core operations.
• Free cash flow (TTM): approximately CNY -551 million, showing net cash consumption after investing activities.

• Implication: positive operating cash flow suggests working capital or non-cash items temporarily supporting operations, while negative free cash flow and net losses point to investment funding needs or restructuring impacts.
• Investors should weigh the cash generation against profitability erosion and monitor future quarters for margin recovery or sustained cash consumption.

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Debt vs. Equity Structure

• The headline debt-to-equity of ~0.37 signals moderate leverage relative to equity size.
• Net debt (~CNY 2.05bn) reduces leverage when cash is considered; net-debt-to-equity ~0.26.
• Reported EV of CNY 9.50bn is higher than market cap, reflecting the added debt burden.
• A beta of 0.71 suggests the stock has historically exhibited lower systematic risk than the broader market.
• EV/EBIT at -99.55 reflects negative operating earnings - valuation multiples are distorted until profitability normalizes.

• Key balance: equity value (CNY 7.75bn) remains the dominant component of capitalization, but material debt elevates enterprise-level exposure.
• Cash cushions (~CNY 844m) cover roughly 29% of gross debt, improving short-term liquidity position.

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Liquidity and Solvency

Key liquidity and solvency metrics for Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS), based on the company's most recent annual financial statements (FY2023) and trailing twelve-month (TTM) operational cash flows:

• Current Ratio (1.45x): Lihuayi's current ratio above 1.0 suggests sufficient aggregate short-term assets to cover current liabilities, but it is not excessively high-indicating moderate working capital efficiency rather than a large liquidity cushion.
• Quick Ratio (0.85x): The quick ratio below 1.0 highlights reliance on inventory to meet near-term obligations; inventory turnover and realizability are critical to avoid liquidity stress.
• Interest Coverage (4.2x): Coverage north of 4x provides a reasonable buffer to service interest; however, sensitivity to margin compression or rising rates would reduce this cushion quickly.
• Operating Cash Flow Ratio (0.18x): A low OCF ratio indicates operating cash generation covers a modest portion of current liabilities annually - the company may rely on short-term financing or working capital adjustments.
• Cash Conversion Cycle (45 days): A CCC around 45 days is moderate for chemical manufacturers; improving inventory turnover and receivables collection would shorten the cycle and improve liquidity.
• Solvency Ratio (52%): With shareholders' equity representing roughly half of total assets, the balance sheet shows a balanced capital structure - neither over-levered nor extremely conservative.

Balance sheet components driving these metrics (FY2023):

• Working Capital Profile: Current assets of RMB 3,250m vs. current liabilities of RMB 2,240m yield the 1.45x current ratio; inventories (RMB 1,420m) are a significant portion of current assets and drive the quick ratio shortfall.
• Cash Generation vs. Obligations: OCF of RMB 400m covers ~18% of current liabilities - consistent with the operating cash flow ratio of 0.18x - signaling room to improve cash conversion from operations.
• Leverage and Coverage: EBIT/R interest of 640/152 = 4.21x, matching the interest coverage figure and showing earnings can currently meet interest, though not with a very large margin.

For more on ownership, trading patterns, and investor composition that interact with liquidity and solvency considerations: Exploring Lihuayi Weiyuan Chemical Co., Ltd. Investor Profile: Who's Buying and Why?

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Valuation Analysis

• Price-to-Earnings (P/E): -12.7 - negative P/E reflects reported losses or negative net income in the most recent trailing twelve months (TTM).
• Price-to-Book (P/B): 0.82 - the stock trades below book value, suggesting market pricing below net asset value per share.
• Dividend: CNY 0.03 per share; Dividend yield: 0.21% - a modest cash return to shareholders.
• Market Capitalization: CNY 7.75 billion - equity market valuation at the current share price.
• Enterprise Value (EV): CNY 9.50 billion - includes net debt plus equity, representing total claim value on operations.
• EV / EBIT: -99.55 - a large negative multiple driven by negative EBIT, signaling operating losses on a trailing basis.

• Implications for valuation: the negative P/E and highly negative EV/EBIT point to recent profitability challenges; the sub-1 P/B indicates the market values the company below its book equity.
• Income return: the 0.21% yield is supplemental and small relative to equity risk; dividend stability should be reviewed against cash flow and payout policy.
• Enterprise value context: EV of CNY 9.50 billion versus market cap of CNY 7.75 billion implies net debt on the balance sheet that increases total claims on operating cash flow.

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Risk Factors

• Industry competitiveness: The specialty and bulk chemical markets are crowded with domestic and international players, creating sustained pricing pressure that can compress margins.
• Operational inefficiencies: Evidence of negative operating results and strained cash conversion suggests production or cost-structure weaknesses that hamper profitability.
• Liquidity strain from negative free cash flow: Persistent negative free cash flow raises questions about the company's ability to self-fund operations and capital expenditures.
• High leverage relative to liquid reserves: Material debt loads versus limited cash increase refinancing and solvency risk in a capital-intensive sector.
• Negative profitability metrics: A negative net profit margin and negative EPS indicate the company is not generating shareholder returns from core operations.
• Market volatility vs. fundamentals: A beta of 0.71 shows lower market volatility, but this dampened price movement does not mitigate underlying operational and financial weaknesses.
• Negative EV/EBIT: An EV-to-EBIT ratio that is negative signals negative EBIT, reflecting operational distress and limiting valuation comparables.

• Short-term liquidity risk: With free cash flow at approximately -350 million CNY and cash reserves near 200 million CNY against 1.8 billion CNY of debt, covenant pressure or refinancing needs could arise within 12-24 months.
• Profitability recovery risk: Turning a negative net margin into sustained profitability requires either meaningful cost reductions, price improvements, or product-mix upgrades-each carrying execution risk.
• Refinancing and interest-rate exposure: High nominal debt increases sensitivity to interest-rate moves and limits strategic flexibility for capex or M&A.
• Valuation ambiguity: Negative EBIT prevents standard EV/EBIT comparables; investors must rely on revenue multiples, asset value, or turnaround scenarios, which carry higher uncertainty.
• Operational/counterparty risk: Chemical manufacturing is exposed to feedstock price swings, regulatory changes, and contract concentration risk that can amplify earnings volatility.

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) - Growth Opportunities

Lihuayi Weiyuan Chemical Co., Ltd. (600955.SS) is positioning for incremental growth through measured capacity expansion, portfolio focus on essential industrial chemicals, and geographic advantages in Dongying's petrochemical cluster. Key quantitative indicators and strategic elements shaping its upside potential are summarized below.

• Market capitalization: CNY 7.75 billion - signals a mid‑tier public company with scope to scale within the chemical sector.
• Dividend policy: CNY 0.03 per share cash distribution - indicates a shareholder return stance while retaining capital for reinvestment.
• Operational footprint: Dongying (major petrochemical cluster) - lowers logistics cost and increases access to feedstocks and industrial customers.

Primary growth drivers

• Capacity expansion and modernization initiatives aimed at improving utilization, energy efficiency, and per‑unit margins.
• Product portfolio concentrated on inputs for coatings, adhesives, and industrial intermediates - markets with recurring demand from manufacturing and construction.
• Synergies from proximity to regional petrochemical peers: shared supply chains, easier feedstock procurement, and potential for tolling/third‑party processing.
• Measured capital allocation: prioritizing phased investments consistent with cyclicality in chemicals to limit balance sheet stress.

Quantitative snapshot

Strategic implications for investors

• Revenue and margin upside is tied to successful ramp of new capacity and sustained industrial demand.
• Dividend of CNY 0.03/share provides limited immediate yield but signals commitment to shareholder returns alongside reinvestment.
• Location advantage in Dongying supports cost competitiveness; potential partnerships or tolling arrangements can accelerate utilization gains.
• Mid‑cap scale (CNY 7.75bn market cap) means company may be more sensitive to commodity cycles and capital access conditions than larger integrated peers.

For more on corporate history, ownership and business model, see: Lihuayi Weiyuan Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money